Title:
AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE
Document Type and Number:
WIPO Patent Application WO/2018/121551
Kind Code:
A1
Abstract:
The present invention relates to an azabicyclo-substituted triazole derivative, a preparation method thereof, and an application of the same in medicine. In particular, the present invention relates to a novel azabicyclo-substituted triazole derivative represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a therapeutic agent, especially as an oxytocin antagonist, and a use of the same in preparing a drug for treating or preventing a disease or disorder known or shown to have beneficial effect thereon with oxytocin being suppressed. The definition of each substituent in the general formula (I) is the same as the definition in the specification.
Inventors:
LI XIN (CN)
CHEN YANG (CN)
LIU TAO (CN)
HE FENG (CN)
TAO WEIKANG (CN)
CHEN YANG (CN)
LIU TAO (CN)
HE FENG (CN)
TAO WEIKANG (CN)
Application Number:
PCT/CN2017/118784
Publication Date:
July 05, 2018
Filing Date:
December 27, 2017
Export Citation:
Assignee:
JIANGSU HENGRUI MEDICINE CO (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D401/14; A61K31/4196; A61K31/44; A61P15/00; C07D405/14
Domestic Patent References:
| WO2006092731A1 | 2006-09-08 | |||
| WO2006100588A1 | 2006-09-28 | |||
| WO2007017752A1 | 2007-02-15 | |||
| WO2005028452A1 | 2005-03-31 | |||
| WO2005082866A2 | 2005-09-09 | |||
| WO2006077496A1 | 2006-07-27 | |||
| WO2006092731A1 | 2006-09-08 | |||
| WO2006100588A1 | 2006-09-28 | |||
| WO2006100557A1 | 2006-09-28 | |||
| WO2015180612A1 | 2015-12-03 | |||
| WO2008051493A2 | 2008-05-02 |
Foreign References:
| CN101107243A | 2008-01-16 | |||
| US6979686B1 | 2005-12-27 |
Other References:
AKERLUND ET AL., ANN. NY ACAD. SCI., vol. 734, 1994, pages 47 - 56
GIMPLFAHRENHOLZ, PHYSIOLOGICAL REVIEWS, vol. 81, no. 2, 2001, pages 629 - 683
LIKEWISE, MESTON ET AL., ARCH. GEN. PSYCHIATRY, vol. 57, no. 11, 2000, pages 1012 - 30
MELIS ET AL., NEURO SCIENCE LETTERS, vol. 265, 1999, pages 171 - 174
ALAN D. BORTHWICK, J. MED. CHEM., vol. 53, 2010, pages 6525 - 6538
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 2, 2010, pages 516 - 520
JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 3, 2015, pages 1123 - 1139
See also references of EP 3564231A4
GIMPLFAHRENHOLZ, PHYSIOLOGICAL REVIEWS, vol. 81, no. 2, 2001, pages 629 - 683
LIKEWISE, MESTON ET AL., ARCH. GEN. PSYCHIATRY, vol. 57, no. 11, 2000, pages 1012 - 30
MELIS ET AL., NEURO SCIENCE LETTERS, vol. 265, 1999, pages 171 - 174
ALAN D. BORTHWICK, J. MED. CHEM., vol. 53, 2010, pages 6525 - 6538
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 2, 2010, pages 516 - 520
JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 3, 2015, pages 1123 - 1139
See also references of EP 3564231A4
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: